WILMINGTON – Biopharmaceutical giant Incyte Corp. announced Monday that it has bought into a new collaboration deal on a monoclonal antibody, paying about $152 million to Massachusetts-based clinical stage company Syndax Pharmaceuticals. The exclusive worldwide ...
WILMINGTON – Incyte Corp. reported a “disappointing” conclusion Monday to its study of its blockbuster drug Jakafi to fight the effects of COVID-19 in hospitalized patients. The pharmaceutical company headquartered in Alapocas announced a phase ...
WILIMINGTON – Global biopharmaceutical company Incyte announced April 2 that it was studying whether it could repurpose its blockbuster drug Jakafi to aid in the treatment of COVID-19 patients. The company headquartered in Alapocas reported ...
In 1991, CB Research and Development was founded in a 2,000-square-foot facility to synthesize specialized chemical compounds for drug-makers. There were three employees. That same year, Incyte was founded in Palo Alto, California, to focus ...
Incyte Corporation has announced that the U.S. Food and Drug Administration (FDA) has approved Jakafi® (ruxolitinib) for the treatment of steroid-refractory acute GVHD in adult and pediatric patients 12 years and older. Jakafi is the ...